Annual REPORT 2023

ICCBBA

Table of Contents

Leadership Insight

A Reflection From the Board Chair and Excutive Director

2023 felt like a busy year for ICCBBA as the world continued to emerge from the pandemic. ICCBBA was represented at 21 events and conferences during the year, 12 more than 2022. We delivered our first webinars in October and November 2023. These were very well received which encourages us to continue to develop training and education content for our end-users. Certificates were also introduced for facilities to show that they are registered with ICCBBA. The certificates help facilities to meet accreditation or regulatory requirements and help increase awareness of ISBT 128 among the facilities' staff. The Enterprise Grant was substantially increased, making $80,000 available for projects, up from $30,000 in previous editions.

Dr. Tim Pruett completed his term as Chair of the Board and was succeeded by Dr. Zbigniew M. Szczepiorkowski. Dr. Diletta Trojan from Italy joined the board bringing a European tissue bank perspective. Dr. Diego Ponzin unfortunately had to step down due to competing professional priorities, but we are very grateful for his contributions during his time.

The May 2023 Board meeting in Sao Paulo, Brazil, was a highlight because of the opportunities to interact with local blood and cell therapy experts. Board members were able to visit local facilities and see how they are working with ISBT 128 in their centres, all of which helps to build networks and relationships for future collaborations. We are grateful to our local hosts for their time.

In 2023, we also sadly said goodbye to Donald Gironne who passed away in May. With over 17 years of dedicated service in the Americas Technical Advisory Group (ATAG), he played an instrumental role in the development of ISBT 128 data structures, ensuring the seamless flow of information within the blood transfusion community. His knowledge and passion will be greatly missed.

In terms of wider healthcare informatics standards, ICCBBA was admitted to the Joint Initiative Council for Global Health Informatics Standardization alongside other organisations such as HL7, GS1, SNOMED and LOINC. As a small and specialised Standards Development Organisation, ICCBBA hopes to learn from the experience of our colleagues and contribute to making interoperability work for patient safety and outcomes.

New staff arrived to replace departing colleagues. After almost 9 years, Matt Delgado, Business Director, left ICCBBA to take up another position elsewhere in March 2023. We welcomed Christina Salinas as the Global Development Manager.

On behalf of ICCBBA, we would like to thank our fellow Board members and volunteer experts who make up our Technical Advisory Groups for their time, expertise and enthusiasm. We would also like to acknowledge the critical work done by the ICCBBA office team in maintaining the standard and supporting its further development in an ever-changing world.

Zbigniew M Szczepiorkowski
2023 Board Chair

Eoin McGrath
Executive Director

About ICCBBA

ICCBBA is an international non-state actor that manages, develops, and licenses ISBT 128, the international information standard for the terminology, coding and labeling of medical products of human origin (MPHO). ISBT 128 is designed to best identify MPHO and facilitate efficient, appropriate, and safe use for recipients. ICCBBA also manages the allocation of globally unique identifiers to licensed facilities and maintains the ISBT 128 Standard, international databases for Facility Identification Numbers and Product Description Codes, supporting documentation, and educational materials.

In its efforts to maintain and enhance the ISBT 128 Standard, ICCBBA brings together experts from clinical, scientific, technical, and informatics backgrounds, representatives from scientific and professional societies, and observers from regulatory authorities and industry to review and update the ISBT 128 Standard to ensure it continues to meet the needs of its users.

ICCBBA is a tax-exempt, nonprofit organization as described in Section 501(c)(3) of the US Internal Revenue Code. These regulations stipulate that the organization cannot be organized or operated for the benefit of private interests, and no part of the organization's net earnings may inure to the benefit of any private shareholder or individual. Within its Articles of Association, ICCBBA is required to be organized and operated exclusively for charitable, scientific, and educational purposes.

ISO 9001 QMS Certified ASR Registrar

ICCBBA is ISO 9001:2015 certified.

VISION

Global adoption of ISBT 128 for all medical products of human origin (MPHO).

MISSION

Enhancing patienty safety by promoting and managing the ISBT 128 international information standard for use with MPHOs.

Facility Distribution

New Registered Facilities 2023

Australia	6
Bahrain	1
Belgium	3
Brazil	3
Canada	9
China	1
Colombia	1
Czech Republic	1
France	2
Germany	1
Greece	1
Hungary	3
India	1
Indonesia	1
Israel	3
Japan	1
Mexico	1
Pakistan	3
Poland	6
Portugal	1
Saudi Arabia	12
Singapore	1
Slovakia	3
South Africa	1
Spain	4
Taiwan, China	1
Turkey	1
United Arab Emerates	4
United Kingdom	6
United States	56
Vietnam	1
---	---
Grand Total	**139**

2023 Distribution of FINs by World Bank Region



2023 ISBT 128 Registrations by World Bank Income Class Groups



Board of Directors

Positions as of May 2023

Zbigniew Szczepiorkowski
Chair
United States

Cellular therapy, clinical use of apheresis products, pathology, transfusion medicine.

Tim Pruett
Vice Chair
United States

General surgery, infectious diseases, internal medicine, transplantation.

Matthew Kuehnert
Treasurer
United States

Adverse events in transfusion and transplantation, biovigilance, infectious diseases, internal medicine.

Kelly Tilleman
Secretary
Belgium

Assisted reproduction, fertility preservation, genetic testing, human reproduction and embryology, in vitro maturation of oocytes starting from ovarian cervical tissue, lab quality, proteomics, quality and safety of tissues and cells, reproductive tissues and cells.

Mohammed Farouk
Egypt

Blood transfusion, human tissues and cells, injury prevention, patient blood management, research methodologies.

Joy Mammen
India

Blood transfusion, medicine, hematology, laboratory informatics, pathology, transfusion medicine.

Martin Hildebrandt
Germany

Internal medicine, hematology and oncology cell-based gene therapies, transfusion medicine.

Mickey Koh
United Kingdom/Singapore

Cell therapy, transfusion, clinical hematology, clinical trials, collaborative research, blood transfusion, regenerative medicine, stem cell transplantation.

Welcome

Diletta Trojan
Italy

Tissue banking, Colon cancer research, Mouse models, Genetic tests

Farewell

Diane Wilson
United States

Diego Ponzin
Italy

2023 ICCBBA Staff



Eoin McGrath
Executive Director

Karen Moniz
Technical Director

Erwin Cabana
Technical Manager

Alex Weston
Controller

Mónica Freire
Standards Documentation Manager

Betty Perez
Executive Assistant

Ryan Ruiz
Information Standards Specialist II

Alex Garlets
Information Standards Specialist

Allison Hiebert
Administrative Assistant II - Accounting

Cristina Villegas
Administrative Assistant - Accounting

Wendy Becerra
Administrative Assistant II - Global Development

Andrew Price
Creative Services Coordinator

Farewell

Matt Delgado
Business Director

Briana Rice
Education Specialist

Welcome

Chris Salinas
Global Development Manager

Forging Excellence

Development of Standards and Product Codes

ISBT 128 Standards are frequently reviewed and updated to reflect new information and ensure consistency between related standards. Changes are detailed in a change table within each document so that users can readily assess updated material. Multiple standards were updated in 2023, including the following:

ST-001 v6.2.2

ISBT 128 Standard Technical Specification

The purpose of this document is to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy products, tissues, milk, and organs, as well as those plasma derivatives for which ABO is relevant.

Subject Area: **ISBT 128**

ST-004 v2.0.1

ISBT 128 Standard Labeling of Cellular Therapy Products

This document is intended to help facilities, label vendors, and software developers design appropriate ISBT 128 labels for cellular therapy products. Greater detail is given for labeling than that provided in the ISBT 128 Technical Specification.

Subject Area: **Cellular Therapy**

ST-005 v2.0.1

ISBT 128 Standard Labeling of Blood Components

This document is intended to help facilities, label vendors, and software developers design appropriate ISBT 128 labels for blood products.

Subject Area: **Blood**

ST-009 v1.2.0

ISBT 128 Standard Labeling of Ocular Tissue

This document is intended to help facilities and software developers design appropriate ISBT 128 labels for ocular tissue products. Greater detail is given for labeling than that provided in the ISBT 128 Technical Specification.

Subject Area: **Ocular Products**

Forging Excellence cont.

Development of Standards and Product Codes

ST-018 v1.2.0

ISBT 128 Standard Labeling of Collection Products for Cellular Therapy Manufacturing

This document provides instructions for the labeling of apheresis collection products for sponsor cellular therapy clinical trials and manufacturing.

Subject Area:
Cellular Therapy

ST-023 v1.0.1

ISBT 128 Standard for Base Labels

The purpose of this document is to provide specifications for blood and cellular therapy base labels that carry ISBT 128 Data Structures. The specifications contained in this document on the standardized placement of linear bar codes on the base label were previously defined in the documents ISBT 128 Standard Labeling of Blood Components (ST-005) and ISBT 128 Standard Labeling of Cellular Therapy Products (ST-004).

Subject Areas:
Blood
Cellular Therapy

ST-026 v1.0.1

ISBT 128 Standard for the Medical Products of Human Origin (MPHO) Unique Identifier

The purpose of this document is to provide standards for the coding of the Medical Products of Human Origin (MPHO) Unique Identifier. It provides the rules for the construction of the MPHO Unique Identifier, a single data item providing globally unique instance identification and designed to optimize the electronic capture of critical MPHO traceability information.

Subject Area:
Electronic Messaging

ST-027 v1.3.0

ISBT 128 Dictionary of Standard Data Elements

The purpose of this document is to provide a dictionary of standard data elements. The document describes the data elements defined within ISBT 128 and identifies the corresponding unique resource identifier for each element. These data elements are for use in electronic messages.

Subject Area:
Electronic Messaging

Forging Excellence cont.

Development of Standards and Product Codes

In 2023, requests for blood product description codes were the most active, followed by requests for cellular therapy codes.

ISBT 128 Product Description Code requests are reviewed by ICCBBA's technical department.

Total ISBT 128 Product Description Codes in 2023



Additional ISBT 128 Product Description Codes Added in 2023



Forging Excellence cont.

Education and Training

ICCBBA Webinars

Cracking the Code:
An Overview of ISBT 128 Product Codes
October 2023

Move Beyond the Label
with the MPHO Unique Identifier
November 2023

isbt128.org/presentations

Collaborative Webinars

American Society for Apheresis (ASFA) Webinar – A Standardized Format for the Chain of Identity (CoI) Identifier
March 2023

Utilizing the Chain of Identity Identifier in Cell Therapy Manufacturing – 30th Autumn Symposium of The Japan Society of Transfusion Medicine and Cell Therapy (JSTMCT)
October 2023

Videos

ISBT 128 Clinical Trials Product Description Codes
March 2023

Collaborative Publication

International Society for Blood Transfusion Guidelines for Traceability of Medical Products of Human Origin

Ashford P, Butch S, Barhoush AO, Bolton W, Cusmai M, Espensen L, et al. International Society for Blood Transfusion Guidelines for Traceability of Medical Products of Human Origin. Vox Sang. 2023; 118: 587–597.

Technical Advisory Groups

Introduction

ICCBBA Technical Advisory Groups (TAGs) are essential to the ongoing development of the ISBT 128 Standard. These groups provide stakeholder input and educational and technical support to facilities implementing ISBT 128. TAGs operate through consensus decision-making to ensure the best possible solutions are utilized for the ISBT 128 Standard and MPHO product identification.

TAG participants are experts in various MPHO fields and tend to be spread over large geographical areas.

TAG Operations and Processes

TAG groups advise on the ongoing development of the ISBT 128 Information Standard to support new developments in various fields of transfusion and transplantation. TAGs focus on standardization of terminology and product names for medical products of human origin. TAGs generate, review, and comment on proposed changes to the ISBT 128 Standard and supporting documents. TAGs also provide advice and support to facilities introducing ISBT 128 and help to prepare educational materials and tools to support the implementation of ISBT 128. TAG members also promote the adoption of the ISBT 128 Standard in facilities around the world.

Each year, TAGs may have one face to face meeting. They also meet virtually in accordance with their needs. These forums allow TAG members from different areas of the world to contribute asynchronously and frequently negate the need to schedule meetings. TAG volunteers are experts in various fields of medicine, regulation, and technology. TAG members represent a variety of medical societies, standards setting bodies, national health organizations, regulatory agencies, and software developers.

Volunteer Highlights

A special thank you to all TAG volunteers for their invaluable contributions. In addition, ICCBBA recognizes the many long-term volunteers who have contributed to ISBT 128's growth in recent years.

For more information on ICCBBA Technical Advisory Groups, please visit our Committees webpage: ISBT 128 | ICCBBA | Committees

Technical Advisory Groups cont.

TAG Information

	2023 Meeting Totals by MPHO
Blood	3
Cellular Therapy	6
Milk	2
Regenerative Medicine	1
Reproductive Technology	1
Standards Committee	1
Tissue	1
Total	**13**

TAG Chairs

Standards Committee, APTAG, & TAG-IT
Wayne Bolton – Australia

ATAG
Kathleen Hopping – United States

ARTTAG
Kelly Tilleman – Belgium

CTCLAG
Zbigniew Szczepiorkowski – United States

EBTAG
Diego Ponzin – Italy
Kristin Mathes – United States

EMATAG
Jolanta Antoniewicz-Papis – Poland

ETTAG & ITTAG
Izabela Uhrynowska-Tyszkiewicz – Poland

MBTAG
Debbie Barnett – United Kingdom

NATTAG
Jelena Holovati – Canada

RMTAG
Martin Hildebrandt – Germany

New TAG Chair in 2023
Kristin Mathes – EBTAG

Chair Terms Concluding 2022
Special thanks to the contributions of:
Diego Ponzin - EBTAG

Technical Advisory Groups cont.

TAG Activities

Assisted Reproductive Technology Technical Advisory Group

ARTTAG

ARTTAG met in 2023 to discuss labeling containers with multiple oocytes or embryos. The group also discussed changing the committee's name from ARTTAG to MARTAG—Medically Assisted Reproduction Technical Advisory Group—as MAR is a broader term that includes all ART procedures and assisted insemination per its definition in the international glossary.

Blood Technical Advisory Groups

Americas Technical Advisory Group (ATAG)

Europe, Middle East, and Africa Technical Advisory Group (EMATAG)

Asia Pacific Technical Advisory Group (APTAG)

Blood TAGs are helping ICCBBA develop new data elements for inventory status, patient adverse events, and donor adverse events. This initiative is in the research phase, and proposals will be shared with the committees for voting. ATAG met in Nashville, Tennessee, on October 13, 2023, for the first group face-to-face meeting since the COVID lockdown. EMATAG did not meet in 2023 but provided feedback for blood terminology through online forum. APTAG did not have activity in 2023.

Cellular Therapy Coding and Labeling Advisory Group

CTCLAG

Due to the rapid growth in cellular therapy, CTCLAG holds frequent meetings. In 2023, CTCLAG contributed to 6 of the 15 total TAG meetings. The committee contributed to education efforts for the Implementation Guide Using the ISBT 128 Chain of Identity (CoI) Identifier (IG-050). The group also contributes to developing cell and gene therapy articles, new ISBT 128 terminology for extracellular vesicles, and efforts to differentiate CAR T Cells.

Milk Banking Technical Advisory Group

MBTAG

The Milk Banking Technical Advisory Group is helping to update the ISBT 128 Standard Labeling of Human Milk Banking Products (ST-013). MBTAG is also supporting updating the International Consensus Statement on the Terminology, Coding and Labeling of Human Milk Donations. The group provided feedback on new terminology for Premature Colostrum and Transitional Milk and updates to existing terminology, including Pre-Term, Term, and Colostrum. To ensure the terminology supports global traceability, the group recommended the terminology be circulated to members of the Global Alliance of Milk Banks and Associations (GAMBA).

Technical Advisory Groups cont.

TAG Activities

Regenerative Medicine Technical Advisory Group

RMTAG

The RMTAG assisted ICCBBA in developing an abstract highlighting the need for a globally consistent coding and labeling system for tissue-engineered products (TEPs). RMTAG provided feedback to ICCBBA, recognizing that TEPs may be regulated as biologics or medical devices. The committee recommended creating a labeling standard that aligns with biologics regulations. RMTAG will also engage with industry stakeholders across different geographical regions to ensure that the new standard supports TEP traceability worldwide.

Technical Advisory Group for Information Technology

TAG-IT

TAG-IT meets asynchronously via forum to review IT related standards. ST-027 - Dictionary of Standard Data Elements was updated in 2023 with the assistance of TAG-IT.

Tissue Technical Advisory Groups

Eye Bank Technical Advisory Group (EBTAG)
European Tissue Technical Advisory Group (ETTAG)
International Tissue Technical Advisory Group (ITTAG)
North America Tissue Technical Advisory Group (NATTAG)

The Tissue TAGs play a crucial role in developing the ISBT 128 tissue terminology, which supports global harmonization and enhances traceability and safety. Although EBTAG and ITTAG did not convene in 2023, they shared their feedback on tissue terminology through online consultation. NATTAG held a virtual meeting in April 2023 to discuss organizational updates and identify needs related to tissue terminology.

Closing Notes:

ICCBBA's Technical Advisory Groups are pivotal in expanding and enhancing standardized terminology within the ISBT 128 Standard. By providing expert insights, collaborations, and recommendations, these Groups have helped ensure that ISBT 128 harmonized terminology aligns with the evolving needs within the transfusion and transplantation communities. ICCBBA extends its deepest gratitude to its committees for their invaluable contributions to enhancing patient safety through the ISBT 128 Standard.

Global Relationships

2023 Meetings and Events

January 17-20	*Miami, United States*	Advanced Therapies Week 2023 - Phacilitate
March 07-09	*Boston, United States*	Supply Chain and Logistics for Cell Therapies Summit - Hanson Wade
March 13-15	*Denver, United States*	Industry Working Group (IWG) 2023
April 12-14	*Barcelona, Spain*	Cell and Gene Meeting on the Med
April 24-26	*Paris, France*	49th Annual Meeting of the EBMT
April 26-28	*Minneapolis, United States*	ASFA 2023 Annual Meeting - American Society for Apheresis
May 31 - June 3	*Paris, France*	ISCT 2023 Paris Annual Meeting - International Society for Cell & Gene Therapy
June 6	*Barcelona, Spain*	openEHR International Conference
June 17-21	*Gothenburg, Sweden*	ISBT Gothenburg 2023 - International Society of Blood Transfusion (ISBT)
June 18-19	*Stadt Hanau, Germany*	13th International Donor Registry Conference (IDRC) and WMDA Global Meeting
August 23-24	*Bethesda, United States*	AABB Blood Bank and Transfusion Standards (BBTS) Committee Meeting
August 30 - September 1	*Boston, United States*	8th Annual CAR-TCR Summit – Hanson Wade
September 5-6	*Stockholm, Sweden*	SoHO-Net Tissues and Cells (TC) and Medically Assisted Reproduction (MAR) group meeting - European Centre for Disease Prevention and Control (ECDC)
September 5-7	*Estoril, Portugal*	Advanced Therapies Europe - Phacilitate
September 8-10	*Houston, United States*	ISCT North America 2023 Regional Meeting - International Society for Cell & Gene Therapy
September 17-20	*National Harbor, United States*	2023 AATB Annual Meeting – American Association of Tissue Banks
October 1-3	*Llafranc, Spain*	Bioprocessing and Manufacturing of Gene and Cell Therapy Products Course, European Society for Animal Cell Technology (ESACT)
October 3-5	*São Paulo, Brazil / Virtual*	GS1 Healthcare Conference
October 14-17	*Nashville, United States*	2023 AABB Annual Meeting - Association for the Advancement of Blood & Biotherapies
October 25-27	*Madrid, Spain*	7th International Congress of the European Milk Bank Association (EMBA)
November 22-24	*Zagreb, Croatia*	31st Congress of the European Association of Tissue and Cell Banking (EATCB)

Global Relationships cont.

Collaborations			
Association for the Advancement of Blood & Biotherapies		ICCBBA is represented on the AABB IS Committee, Blood Bank and Transfusion Service Standards Committee, Cell Therapy Standards Committee, and the Cell Therapy Circular of Information Task Force. AABB is represented on ICCBBA's CTCLAG and ATAG Committees.	
Alliance for Regenerative Medicine	ICCBBA has been a member of the Alliance for Regenerative Medicine since 2022 under Foundations, Associations, & Patient Advocates.	European Commission	ICCBBA has an agreement with the European Commission to provide product codes for use in the Tissue Establishments compendium supporting the Single European Code for tissues and cells.
FDA, SFDA	ICCBBA is recognized as a UDI issuing agency by FDA (USA), SFDA (Saudi Arabia) and the EU.	GMDN	ICCBBA has a Memorandum of Understanding with GMDNA, the organization responsible for the Global Medical Device Nomenclature (GMDN) used to identify medical devices.
GS1	ICCBBA has collaborated with GS1 since 2007 with a Memorandum of Understanding in place and regularly renewed since then.	HL7 FHIR	ICCBBA is an active participant in the HL7 FHIR Orders and Observations Healthcare Product group impacting the enhanced BiologicallyDerivedProduct resource.
ISBT, WMDA matching donors • serving patients	ICCBBA has Memorandums of Understanding with ISBT and WMDA.	ISO	ICCBBA sits on the ISO US TAG to TC 215 Committee.
	ICCBBA joined the Joint Initiative Council in December 2022.	STANDARDS COORDINATING BODY REGENERATIVE MEDICINE	ICCBBA is one of several Standards Development Organizations collaborating within the Standards Coordinating Body network SDOs & Other Organizations Developing Standards — Standards Coordinating Body.
USCDI	The integration of ISBT 128 coding into the USCDI under Biologically Derived Product Interoperability Standards Advisory (ISA) (healthit.gov) has garnered increasing support over the last three years.	WBMT WWW.WBMT.ORG	ICCBBA is a member society of the Worldwide Network of Bone Marrow Transplantation.

Global Relationships cont.

Collaborations				
Association for the Advancement of Blood & Biotherapies	AEBA Association of Eye Banks of Asia	APBMT Asia-Pacific Blood and Marrow Transplantation Group	ASFA American Society for Apheresis	ASTCT American Society for Transplantation and Cellular Therapy
BAA Biotherapeutics Association of Australasia	Asia Cornea Society	eba European Blood Alliance	Eye Bank Association of America	EBAANZ
E.B.A.I Let your eyes change someone's life	EBMT	European Eye Bank Association EEBA	emba	EMBMT Eastern Mediterranean Blood and Marrow Transplantation
Fact Foundation for the Accreditation of Cellular Therapy at the University of Nebraska Medical Center	GAP	ISBT	International Society ISCT Cell & Gene Therapy®	JACIE Joint Accreditation Committee ISCT | EBMT
LABMT Latin American Blood & Marrow Transplantation	Human Milk Banking Association of North America	nmdp Find Cures. Save Lives.	WBMT www.wbmt.org	WMDA

ICCBBA is a Non-State Actor in Official Relations with the WHO.

Enterprise Grant

Celebrating Our 2023 Enterprise Grant Winner

ICCBBA is delighted to spotlight the recipient of our 2023 Enterprise Grant: the Safe Blood for Africa (SBFA) Foundation, for their transformative project at the Yaoundé University Teaching Hospital Blood Service in Cameroon.

Project Overview

Led by Pr. Claude Tayou Tagny, Country Project Coordinator for the SBFA Foundation, this initiative focused on the Improvement of the Quality Management System through the Installation of a Data Management and Labeling System. The project ran from 10th September 2021 to 13th July 2022, delivering critical advancements in the operational efficiency and traceability of blood products at the Yaoundé University Teaching Hospital.

Vendors

The ISBT 128 Information Standard and its accompanying databases, software, reference tables, and documentation are protected by copyright. The use of the ISBT 128 Standard is limited to vendors who are registered and licensed with ICCBBA. Registration with ICCBBA not only provides Licensed ISBT 128 Vendors with the benefits outlined on the Vendor Benefits page but also provides the licensed organization with access to the password-protected areas of the ICCBBA website. These copyrighted files are updated regularly; thus, it is highly recommended that Licensed ISBT 128 Vendors download the most recent publications of these copyrighted files to ensure that their products/services adhere to the most up-to-date ISBT 128 information.

The year 2023 ended with a total of **114 actively Licensed ISBT 128 Vendors**.
Of these, five were newly licensed with ICCBBA in 2023: Player srl, MedGEO Inc, tCare Digital Systems, Shandong Weigao Group Medical Polymer Co. Ltd., and Arabian House Industries Factory.

In 2023, ICCBBA began a project to enhance the licensed ISBT 128 Vendor Profiles presented within the ISBT 128 Vendor Lookup Tool. The early stages of this project included gathering information to determine the project's scope.

A breakdown of the services provided, the country in which the ISBT 128 Licensed Vendors are headquartered, and the regions reported to be served by the 114 ISBT 128 Licensed Vendors are provided as follows:



Vendors cont.

ISBT 128 Licensed Vendor Headquarters Country



Specified Regions Served by ISBT 128 Vendors



2023 Balance Sheet

Assets

Current Assets		
Cash and cash equivalents	$	433,773
Investments		4,286,976
Accounts receivable, net		140,648
Prepaids		19,711
Total current assets		**4,881,108**
Noncurrent Assets		
Property and equiptment, net		18,091
Operating lease right-of-use assets		252,736
Deposits		6,254
Total noncurrent assets		277,081
Total assets		**$ 5,158,189**

Liabilities and Net Assets

Current Liabilities		
Accounts payable	$	33,272
Accrued wages and benefits		119,278
Operating lease liabilities		78,283
Deferred revenue		32,140
Total current liabilities		**262,973**
Noncurrent liabilities		
Operating lease liabilities, net of current portion		174,453
Total liabilities		**437,426**
Net assets		
Without donor restrictions		
Undesignated		2,589,038
Designated		2,131,725
Total net assets		**4,720,763**
Total liabilities and net assets		**$ 5,158,189**

Statement of Cash Flows

Year Ended December 31, 2023

Cash flows from operating activities		
Change in net assets	$	707,889
Adjustments to reconcile change in net assets		
to net cash provided by operating activities:		
Bad debt		71,943
Depreciation		10,655
Net realized and unrealized gain on investments		(368,467)
Change in operating assets and liabilities:		
Accounts receivable		(96,926)
Prepaids		(7,398)
Accounts payable		26,175
Accrued wages and benefits		(2,558)
Deferred revenue		26,040
Net cash provided by (used in) operating activities		367,353
Cash flows from investing activities		
Purchase of property and equipment		(8,550)
Proceeds from sale of investments		3,481,010
Purchase of investments		(4,155,900)
Net cash provided by (used in) investing activities		(683,440)
Net change in cash		(316,087)
Cash, beginning of year		749,860
Cash, end of year	**$**	**433,773**

Statement of Functional Expenses

	Program Services	General and Administrative	Total
Current Assets			
Salaries and benefits	$ 956,162	$ 285,370	$ 1,241,532
Management consultant	130,261	43,120	173,381
Program, conferences, and meetings	61,176	10,547	71,723
Rent	64,810	21,784	86,594
Professional fees	94,670	56,987	151,657
Insurance	-	26,744	26,744
Bank and credit card fees	-	60,603	60,603
Donations	43,033	-	43,033
Depreciation	-	10,655	10,655
Education and promotion	62,945	5,753	68,698
Staff business travel	9,212	27,638	36,850
Office supplies	9,126	6,854	15,980
Dues and subscriptions	-	12,237	12,237
Telephone	3,884	971	4,855
Internet services	21,148	5,004	26,152
Postage	1,154	289	1,443
Other	11,898	11,754	23,652
Staff training	1,940	1,940	3,880
Printing	113	-	113
Bad debt	71,943	-_____	71,943
	$1,543,475	**$588,250**	**$2,131,725**

2023 Income Statement

	(US Dollars)
Revenue	
Registration and license fees	$ 2,307,688
Expenses	
Program services	1,543,475
General and administrative	588,250
Total expenses	**2,131,725**
Net income from operations	175,963
Investment income (loss)	531,926
Change in net assets without donor restrictions	707,889
Net assets without donor restrictions, beginning of year	4,012,874
Net assets without donor restrictions, end of year	**$ 4,720,763**

Goals and Stategic Plans

ICCBBA is Working on Four Main Strategic Lines

01. Enhance User Engagement and Understanding

Empower Users:

Implement surveys, create more opportunities for users to interact with the ICCBBA team, and foster networking to strengthen the user community's voice.

User-Centric Education:

Develop innovative educational resources in user-friendly formats, enabling users to grasp the essence of ISBT 128 and harness its full potential.

Data-Driven Insights:

Collect and analyze data to gain insights into user engagement levels and activity within various MPHO fields, driving informed decision-making.

02. Elevate Communication Effectiveness

Dynamic Newsletters:

Revamp newsletters and announcements, infusing them with dynamism and relevance to engage and inform stakeholders effectively.

Social Media Amplification:

Boost ICCBBA's online presence across social media platforms, using them as a dynamic communication channel to reach a broader audience.

Strategic Alliances:

Cultivate and maintain active relationships with professional MPHO associations and other stakeholders. Leverage their networks to expand ICCBBA's reach and impact.

03. Enhance ISBT 128 Interoperability

Cross-Sector Collaboration:

Actively collaborate with other Standards Development Organizations within the healthcare data sector. Aim to minimize data exchange barriers, fostering seamless interoperability between electronic systems that use ISBT 128 data.

04. Optimize Operational Efficiency

Digital Transformation:

Harness the power of existing and emerging digital tools to enhance the user experience. Streamline processes to make ICCBBA's services more accessible, efficient, and user-friendly.

Mailing Address:

PO Box 11309
San Bernardino, CA 92423-1309
United States

Office Address:

1901 Orange Tree Ln, St. 200
Redlands, CA 92374
United States

Phone:

+1 909 793-6516

Fax:

+1 909 793-6214

Email:

support@isbt128.org

isbt128.org

Help Desk

Newsletter

Follow Us Online!